top of page
eyes

SIGHT
FOR
LIFE

Transforming lives by developing innovative treatments for ocular diseases that helps restore sight for life

ABOUT

Theialife is a U.S. incorporated, late-stage clinical ophthalmology company, focused on high-impact innovation and an unyielding commitment to advancing breakthrough therapies with the potential to transform standards of care, prevent sight deterioration, restore vision, and improve patients’ lives.

NOVEL PIPELINE

Leveraging a pipeline of differentiated assets spanning early discovery through late-stage clinical programs, Theialife is advancing unique therapies and formulations to address some of the most pressing unmet needs in global ophthalmology.

MYOPIA, THE SILENT EPIDEMIC

Our lead asset, ND10 is poised to become the first oral therapy for early-onset-pediatric myopia and is set to enter global Phase III clinical trials in 2026. 20 years of compassionate clinical use in Denmark with no safety signals reported.

Our lead asset, 7MX is poised to become the first oral therapy for early-onset-pediatric-myopia and is set to enter global Phase III clinical trials in 2025.

INFOGRAPH 1.webp
INFOGRAPH 2.webp

World's First Clinical Phase-3 Ready Oral Therapeutic For Pediatric  Myopia

3B.png

Myopia is when the eye grows too long and causes blurred vision. Commonly referred to as a short-sightedness which causes blurred distant vision. High Myopia (defined as < -6 diopters) is caused by excess elongation of the eye.

20 years of compassionate clinical use in Denmark, with nil reported adverse effects.

Myopia free kid laughing

HOW IT WORKS

Its unique mechanism of action is a non-selective antagonist of the adenosine receptors, designed to limit the progression of myopia.

 

ND10 increases the bio-mechanical strength of the sclera and prevents eye elongation to inhibit myopia progression.

PROPRIETARY OPHTHALMOLOGY PLATFORM

An innovative platform that addresses various ophthalmology unmet needs using novel molecules.

Our lead molecular platform that has the capability to address various indications including Pediatric Myopia, Dry-Eye Disease & UV-B Cataract.

ND10

Myopia theialife

Using an innovative approach to drug discovery, this molecular platform is uniquely positioned  to address Keratoconus & Corneal blindness.

rHCT3

Stumbling-into-the-brave-new-world-of-gene-editing-_bfb3b5b9-a0a9-46eb-9230-9754e9bce622-2

This molecular platform has a innovative approach to potentially address neovascular age related macular degeneration & Pterygium.

XP

high-through-put-pink-2.jpg

ESG

Pills

Daily disposable contact lenses generate approx. 1 KG of plastic waste per year per user

150 Billion contact lenses produced annually

4 Million (approx.) children using contact lenses to treat myopia

VS.

SUSTAINABLE VISIONARY SCIENCE

1 oral tablet of Theialife's drug produced through fermentation using renewable water sources.

0.1 kg CO2 per tablet.

MEET US AT .

OIS Icon.webp

JOIN US

Building the future 
of ophthalmology

We are on a mission to tackle some of the world's biggest health challenges, trying to find solutions where none exist. At Theialife, we seek partners who want to push back the boundaries of innovation on behalf of patients.

References

  1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006

  2. Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109(3):362-371. Published 2025 Feb 24. doi:10.1136/bjo-2024-325427

bottom of page